Myeloid neoplasms with eosinophilia and FIP1L1-PDGFRA fusion gene: another point of view.

about

Imatinib for the treatment of hypereosinophilic syndromes.

P2860

Q50177622-D5B3A2E7-D2CE-44C5-A381-8149C88A491E

P2860

Myeloid neoplasms with eosinophilia and FIP1L1-PDGFRA fusion gene: another point of view.

Item

http://www.wikidata.org/entity/Q44909035

description

2012 nî lūn-bûn

@nan

2012年の論文

@ja

2012年学术文章

@wuu

2012年学术文章

@zh-cn

2012年学术文章

@zh-hans

2012年学术文章

@zh-my

2012年学术文章

@zh-sg

2012年學術文章

@yue

2012年學術文章

@zh

2012年學術文章

@zh-hant

name

Myeloid neoplasms with eosinophilia and FIP1L1-PDGFRA fusion gene: another point of view.

@en

Myeloid neoplasms with eosinophilia and FIP1L1-PDGFRA fusion gene: another point of view.

@nl

type

Item

label

Myeloid neoplasms with eosinophilia and FIP1L1-PDGFRA fusion gene: another point of view.

@en

Myeloid neoplasms with eosinophilia and FIP1L1-PDGFRA fusion gene: another point of view.

@nl

prefLabel

Myeloid neoplasms with eosinophilia and FIP1L1-PDGFRA fusion gene: another point of view.

@en

Myeloid neoplasms with eosinophilia and FIP1L1-PDGFRA fusion gene: another point of view.

@nl

P1476

Myeloid neoplasms with eosinophilia and FIP1L1-PDGFRA fusion gene: another point of view.

@en

P2093

Slawomira Kyrcz-Krzemien

http://www.w3.org/2001/XMLSchema#string

P2860

A tyrosine kinase created by fusion of the PDGFRA and FIP1L1 genes as a therapeutic target of imatinib in idiopathic hypereosinophilic syndrome.

Hypereosinophilic syndrome: a multicenter, retrospective analysis of clinical characteristics and response to therapy

Relapse following discontinuation of imatinib mesylate therapy for FIP1L1/PDGFRA-positive chronic eosinophilic leukemia: implications for optimal dosing.

Hypereosinophilic syndrome variants: diagnostic and therapeutic considerations.

Durable remission after treatment with very low doses of imatinib for FIP1L1-PDGFRα-positive chronic eosinophilic leukaemia.

Discontinuation of imatinib in patients with chronic myeloid leukaemia who have maintained complete molecular remission for at least 2 years: the prospective, multicentre Stop Imatinib (STIM) trial.

Elevated serum tryptase levels identify a subset of patients with a myeloproliferative variant of idiopathic hypereosinophilic syndrome associated with tissue fibrosis, poor prognosis, and imatinib responsiveness.

Clinical and molecular features of FIP1L1-PDFGRA (+) chronic eosinophilic leukemias.

Safety and efficacy of imatinib in chronic eosinophilic leukaemia and hypereosinophilic syndrome: a phase-II study.

Multilineage involvement of the fusion gene in patients with FIP1L1/PDGFRA-positive hypereosinophilic syndrome.

P304

897-898

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

P356

10.3109/10428194.2012.731601

http://www.w3.org/2001/XMLSchema#string

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P50

Grzegorz Helbig

P577

2012-10-26T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

23025324

http://www.w3.org/2001/XMLSchema#string

Myeloid neoplasms with eosinophilia and FIP1L1-PDGFRA fusion gene: another point of view.

about

P2860

P2860

Myeloid neoplasms with eosinophilia and FIP1L1-PDGFRA fusion gene: another point of view.

description

name

type

label

prefLabel

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698

P356

P1433

P1476

P2093

P2860

P304

P31

P356

P433

P478

P50

P577

P698